# Enanta Pharmaceuticals Inc. (ENTA)

Source: https://www.quantisnow.com/company/ENTA
Generated: 2026-11-13T01:48:00.406Z

- Ticker: ENTA
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2013
- SEC CIK: 0001177648
- Website: enanta.com

## About

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company offers glecaprevir for the treatment of chronic hepatitis C virus, or HCV under the MAVYRET and MAVIRET names. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.

## Latest ENTA news and filings

- 2026-11-04 12:00 UTC [Conference Announcement] [Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences](https://www.quantisnow.com/insight/enanta-pharmaceuticals-to-participate-in-upcoming-investor-conferences-6771193)
- 2026-10-29 20:05 UTC [SEC Form 8-K] [SEC Form 8-K filed by Enanta Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-enanta-pharmaceuticals-inc-6763473)
- 2026-10-28 11:14 UTC [SEC Form 8-K] [SEC Form 8-K filed by Enanta Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-enanta-pharmaceuticals-inc-6760470)
- 2026-10-28 11:00 UTC [Leadership Update] [Enanta Pharmaceuticals Announces Planned Retirement of Longstanding Chief Executive Officer Jay R. Luly, Ph.D. After 23 Years of Company Leadership](https://www.quantisnow.com/insight/enanta-pharmaceuticals-announces-planned-retirement-of-longstanding-chief-executive-officer-6760396)
- 2026-10-26 11:00 UTC [Enanta Pharmaceuticals Announces First Patient Dosed in the RESOLVE Phase 2b/3 Study of Zelicapavir, a Potential First-in-Disease Treatment for Respiratory Syncytial Virus (RSV)](https://www.quantisnow.com/insight/enanta-pharmaceuticals-announces-first-patient-dosed-in-the-resolve-phase-6756890)
- 2026-10-13 11:00 UTC [Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2026](https://www.quantisnow.com/insight/enanta-pharmaceuticals-to-present-data-for-zelicapavir-an-oral-once-daily-6744016)
- 2026-09-01 11:00 UTC [Conference Announcement] [Enanta Pharmaceuticals to Participate in September Investor Conferences](https://www.quantisnow.com/insight/enanta-pharmaceuticals-to-participate-in-september-investor-conferences-6700450)
- 2026-08-14 12:19 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Enanta Pharmaceuticals Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-enanta-pharmaceuticals-inc-6681945)
- 2026-08-12 11:00 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Enanta Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-enanta-pharmaceuticals-inc-6676947)
- 2026-08-10 20:05 UTC [SEC Form 8-K] [Enanta Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/enanta-pharmaceuticals-inc-filed-sec-form-8-k-results-of-operations-6673590)
- 2026-08-10 20:01 UTC [Earnings] [Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026](https://www.quantisnow.com/insight/enanta-pharmaceuticals-reports-financial-results-for-its-fiscal-third-quarter-6673431)
- 2026-08-10 13:00 UTC [SEC Form 4] [Chief Medical Officer Rottinghaus Scott T. covered exercise/tax liability with 1,467 shares, decreasing direct ownership by 6% to 23,787 units (SEC Form 4) (withholding obligation)](https://www.quantisnow.com/insight/chief-medical-officer-rottinghaus-scott-t-covered-exercisetax-liability-with-6673064)
- 2026-07-02 20:56 UTC [SEC Form 8-K] [SEC Form 8-K filed by Enanta Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-enanta-pharmaceuticals-inc-6626175)
- 2026-07-02 20:54 UTC [SEC Form 424B5] [SEC Form 424B5 filed by Enanta Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-enanta-pharmaceuticals-inc-6626148)
- 2026-06-23 21:28 UTC [SEC Form 8-K] [SEC Form 8-K filed by Enanta Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-enanta-pharmaceuticals-inc-6613085)
- 2026-06-23 09:10 UTC [Enanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus](https://www.quantisnow.com/insight/enanta-pharmaceuticals-partner-abbvie-receives-european-commission-approval-of-maviret-6611634)
- 2026-06-18 11:12 UTC [SEC Form 8-K] [Enanta Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure](https://www.quantisnow.com/insight/enanta-pharmaceuticals-inc-filed-sec-form-8-k-regulation-fd-disclosure-6607852)
- 2026-06-18 11:00 UTC [Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the Treatment of Respiratory Syncytial Virus (RSV)](https://www.quantisnow.com/insight/enanta-pharmaceuticals-announces-advancement-of-its-zelicapavir-clinical-development-program-6607825)
- 2026-05-28 11:00 UTC [Conference Announcement] [Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference](https://www.quantisnow.com/insight/enanta-pharmaceuticals-to-present-at-the-jefferies-global-healthcare-conference-6576033)
- 2026-05-13 11:25 UTC [SEC Form S-8] [SEC Form S-8 filed by Enanta Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-s-8-filed-by-enanta-pharmaceuticals-inc-6549644)
- 2026-05-13 11:00 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Enanta Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-enanta-pharmaceuticals-inc-6549597)
- 2026-05-11 20:05 UTC [SEC Form 8-K] [Enanta Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/enanta-pharmaceuticals-inc-filed-sec-form-8-k-results-of-operations-6544810)
- 2026-05-11 20:01 UTC [Earnings] [Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026](https://www.quantisnow.com/insight/enanta-pharmaceuticals-reports-financial-results-for-its-fiscal-second-quarter-6544606)
- 2026-05-04 11:00 UTC [Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026](https://www.quantisnow.com/insight/enanta-pharmaceuticals-to-present-data-for-its-respiratory-syncytial-virus-6527867)
- 2026-04-13 11:00 UTC [Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria](https://www.quantisnow.com/insight/enanta-pharmaceuticals-announces-first-participant-dosed-in-phase-1-clinical-6497094)
- 2026-04-07 11:00 UTC [Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026](https://www.quantisnow.com/insight/enanta-pharmaceuticals-to-present-data-for-zelicapavir-an-oral-once-daily-6490228)
- 2026-03-30 11:00 UTC [Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI)](https://www.quantisnow.com/insight/enanta-pharmaceuticals-to-present-data-for-its-stat6-inhibitor-program-6475772)
- 2026-03-26 22:06 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Enanta Pharmaceuticals Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-enanta-pharmaceuticals-inc-6472103)
- 2026-03-26 12:54 UTC [Analyst Coverage Initiated] [Rodman & Renshaw initiated coverage on Enanta Pharmaceuticals with a new price target](https://www.quantisnow.com/insight/rodman-renshaw-initiated-coverage-on-enanta-pharmaceuticals-with-a-new-6470235)
- 2026-03-26 12:00 UTC [SEC Form 8-K] [Enanta Pharmaceuticals Inc. filed SEC Form 8-K: Other Events](https://www.quantisnow.com/insight/enanta-pharmaceuticals-inc-filed-sec-form-8-k-other-events-6470012)
- 2026-03-13 20:20 UTC [SEC Form 4] [SEC Form 4 filed by Director Vance Terry](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-vance-terry-6447154)
- 2026-03-13 20:19 UTC [SEC Form 4] [SEC Form 4 filed by Director Russell Lesley](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-russell-lesley-6447136)
- 2026-03-13 20:18 UTC [SEC Form 4] [SEC Form 4 filed by Director Peterson Kristine](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-peterson-kristine-6447120)
- 2026-03-13 20:17 UTC [SEC Form 4] [SEC Form 4 filed by Director Hata Yujiro S](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-hata-yujiro-s-6447105)
- 2026-03-13 20:15 UTC [SEC Form 4] [SEC Form 4 filed by Director Foletta Mark G](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-foletta-mark-g-6447081)
- 2026-03-13 20:14 UTC [SEC Form 4] [SEC Form 4 filed by Director Carter Bruce L A](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-carter-bruce-l-a-6447028)
- 2026-03-12 20:05 UTC [SEC Form 8-K] [Enanta Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits](https://www.quantisnow.com/insight/enanta-pharmaceuticals-inc-filed-sec-form-8-k-leadership-update-submission-6444383)
- 2026-03-03 12:00 UTC [Conference Announcement] [Enanta Pharmaceuticals to Present at The Citizens Life Sciences Conference](https://www.quantisnow.com/insight/enanta-pharmaceuticals-to-present-at-the-citizens-life-sciences-conference-6423719)
- 2026-02-23 05:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Enanta Pharmaceuticals Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-enanta-pharmaceuticals-inc-6405887)
- 2026-02-13 21:33 UTC [SEC Form 4] [Chief Legal Officer Kowalsky Matthew Paul was granted 5,493 shares and covered exercise/tax liability with 1,902 shares (SEC Form 4)](https://www.quantisnow.com/insight/chief-legal-officer-kowalsky-matthew-paul-was-granted-5493-shares-6392837)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/ENTA
- Earnings history: https://www.quantisnow.com/earnings/ENTA
- Dividend history: https://www.quantisnow.com/dividends/ENTA
- Insider transactions: https://www.quantisnow.com/insiders/ENTA
- Options chain: https://www.quantisnow.com/options/ENTA
- SEC 8-K filings only: https://www.quantisnow.com/company/ENTA/8-k
- RSS and alerts for ENTA: https://www.quantisnow.com/docs/rss-feeds.md